FeesSafety
Pluang+

Amgen raises 2026 outlook twice; $1,000 invested 5 years ago now worth $2,603 amid strong new drug growth.

Company Fundamentals
17 Nov 2026, 18:52 WIB
24/7 Wall Street
View Source
Bullish
Amgen raises 2026 outlook twice; $1,000 invested 5 years ago now worth $2,603 amid strong new drug growth.

Amgen has raised its 2026 financial outlook twice this year, reflecting strong growth from newer drugs like Repatha, IMDELLTRA, and UPLIZNA, which are offsetting declines in older products affected by biosimilars and pricing pressures. The company's third-quarter revenue grew 8.45% to $10.365 billion, with non-GAAP EPS beating estimates for the sixth consecutive quarter. A $1,000 investment five years ago in Amgen shares has grown to $2,603, outperforming the S&P 500. Investors are optimistic about upcoming products like MariTide, though concerns remain about competition and debt levels. Amgen trades at about 20 times its 2026 EPS guidance, with management expecting stable operating margins in 2027.

As of Nov 18, 2026 00:02 WIB, Amgen shares trade at USD 457.18 on Pluang, down 1.11% for the day. The stock’s market capitalization stands at $250.07 billion, reflecting strong investor interest with 100% buy orders on the platform. Notably, Amgen offers a dividend yield of 2.18%, highlighting its appeal as a health sector investment.

More News (AMGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App